|
|
 |
|
Viewing report
|
|
|
|
Product Profiles: COPD in China - Novel therapies to diversify treatment options
Datamonitor, Nov 2011, Pages: 89
Spiriva has a strong reputation with Chinese physicians due to its robust efficacy, making it the gold standard monotherapy in COPD treatment. Spiriva’s inclusion in the 2009 National Reimbursement Drug List has further driven uptake given the high importance of affordability in Chinese COPD treatment.
Features and benefits
- Understand Chinese market dynamics and the role that reimbursement plays in determining success in the COPD market.
- Learn from successful marketing strategies used for key COPD brands in China.
- Assess how pipeline products compare to each other and how they will compete with established therapies.
- Review important clinical developments for key pipeline agents in China with analysis of the latest clinical trial data.
- Access Datamonitor’s independent clinical and commercial assessment of marketed brands and key pipeline agents for COPD in China.
Highlights
- Although methylxanthine has been largely withdrawn from COPD treatment in major markets, it is still extensively used in China at various disease stages. The drug remains a popular choice for patients with lower income, and the greater tolerance of the drug in Chinese patients has further limited the decline in its prescription.
- A number of novel products are moving through the COPD pipeline. Novartis’s once-daily LABA Onbrez will pose a threat to twice-daily LABAs and is expected to be positioned as an add-on therapy to Spiriva. Onbrez is also the LABA component of QVA149, a LABA/LAMA combination forecast to reach the Chinese market at the end of 2014.
Your key questions answered
- How do currently marketed treatments of COPD in China compare to one another?
- What restrictions will pipeline products for COPD face if approved for the Chinese market?
- Which pipeline products will need to compete with currently established treatments, and which will be positioned as add-on therapies?
- How have companies utilized pricing strategies to see success in the COPD market in China?
|
|
|
|
